Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating the statistical utility and information loss in the transformation of a real-world oncology database from CDISC-SDTM to OMOP-CDM.

ESMO real world data and digital oncology·2026

Same author

Cognitive behavioural therapies with a trauma focus for children and adolescents: a commentary on a systematic review and meta-analysis.

Journal of family & child health·2026

Same author

HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas.

ESMO open·2025

Same author

Fatigue and management of warfighter mental endurance.

BMJ military health·2025

Same author

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026

Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026

Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026

Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026

Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026

Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

[Imatinib-induced DRESS].

J Goldman¹, A-B Duval-Modeste, A Lambert

¹Clinique dermatologique, CHU de Rouen, 1 rue de Germont, Rouen, France.

Annales De Dermatologie Et De Venereologie

|May 7, 2008

Summary

This summary is machine-generated.

Imatinib, a leukemia treatment, can cause DRESS syndrome, a severe drug reaction. This case highlights the importance of recognizing imatinib as a potential trigger for DRESS, even with prior reports.

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Related Experiment Videos

Last Updated: Jul 5, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Area of Science:

Oncology
Dermatology
Pharmacology

Background:

Imatinib is a tyrosine kinase inhibitor used for leukemia treatment.
Drug-induced hypersensitivity reactions pose a clinical challenge.
Drug-induced reaction with eosinophilia and systemic symptoms (DRESS) is a severe adverse drug event.

Observation:

A 77-year-old female with chronic myeloid leukemia developed DRESS.
Symptoms included fever, rash, oral erosions, edema, lymphadenopathy, and hypereosinophilia.
Rechallenge with imatinib led to rapid symptom recurrence.

Findings:

The patient presented with a severe drug-induced reaction consistent with DRESS.
Skin biopsy supported a diagnosis of drug-induced reaction.
Causality assessment indicated imatinib as the likely cause of DRESS.

Implications:

This case underscores imatinib as a potential cause of DRESS.
Physicians should consider imatinib in the differential diagnosis of DRESS.
Careful benefit-risk assessment is crucial when reintroducing imatinib after adverse events.